Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Jazz Pharmaceuticals Q1 2026 Earnings Call - Record Revenue Driven by Zepzelca and XYWAV Momentum
Jazz Pharmaceuticals delivered a record first quarter of 2026, with total revenues surging 19% year-over-year to $1.1 billion. The growth was broad-based, fueled by double-digit expansions across all ...
- Total first-quarter 2026 revenue hit a record $1.1 billion, reflecting 19% year-over-year growth.
- Zepzelca sales surged 60% to $101 million, driven by rapid uptake in the first-line maintenance setting for extensive stage small cell lung cancer.
- XYWAV net product sales increased 18% to $408 million, with 425 net patient adds and 16,600 active patients.
- +7 more takeaways
Neurocrine Biosciences Q1 2026 Earnings Call - Commercial Momentum Accelerates as Pipeline Catalysts Loom in 2027
Neurocrine Biosciences delivered a quarter of undeniable momentum, with total revenue surpassing $800 million for the first time in company history. INGREZZA continues to defy gravity nine years post-...
- Total revenue exceeded $800 million for the first time in company history, representing a 44% year-over-year increase.
- INGREZZA sales reached $657 million, up 20% year-over-year, with management reaffirming 2026 guidance of $2.7 to $2.8 billion.
- CRENESSITY sales annualized past $600 million, driven by steady new patient starts, high persistence, and favorable reimbursement dynamics.
- +7 more takeaways
Versigent Q1 2026 Earnings Call - Strong Start as Standalone with Copper Headwinds and Dividend Launch
Versigent delivered a robust first quarter as an independent company, with revenue rising 9% year-over-year to $2.2 billion and adjusted EBITDA margin holding at 9.2%. The results reflect strong under...
- Revenue grew 9% year-over-year to $2.2 billion, with 3% adjusted growth after excluding FX and commodity pass-throughs.
- Adjusted EBITDA reached $203 million, maintaining a 9.2% margin, though diluted by copper and currency impacts.
- New bookings totaled $2.6 billion, marking the start of 24 new programs and the most major launches in company history.
- +7 more takeaways
Arista Networks Q1 2026 Earnings Call - AI Demand Outpaces Supply, Guiding 27.7% Growth
Arista Networks delivered a robust Q1 2026, with revenue of $2.71 billion (+35% YoY) and raised its full-year growth forecast to 27.7%, targeting $11.5 billion. The company is commanding #1 market sha...
- Revenue of $2.71 billion grew 35.1% year-over-year, beating guidance of $2.6 billion.
- Full-year 2026 revenue growth forecast raised to 27.7%, targeting approximately $11.5 billion.
- AI fabric revenue target increased to $3.5 billion, more than doubling from prior year.
- +7 more takeaways
Lumen Technologies Q1 2026 Earnings Call - Alkira Acquisition Completes Digital Architecture, FCF Guidance Raised
Lumen Technologies reported a solid Q1 2026, with revenue and EBITDA in line with expectations and above consensus. The company’s strategic pivot toward programmable networking and AI-driven infrastru...
- Lumen announced its intent to acquire Alkira for $475 million in cash, targeting a Q3 2026 close to complete its digital architecture.
- The Alkira acquisition extends Lumen’s programmable network into east-west cloud connectivity, complementing existing north-south capabilities.
- Management expects Alkira to accelerate roadmap execution from years to months, inject talent, and provide a marketplace-ready platform.
- +11 more takeaways
Marqeta Inc. Q1 2026 Earnings Call - Marqeta Hits GAAP Profitability as Non-Block Growth Surges 33%
Marqeta delivered a strong first quarter 2026, posting $166 million in net revenue, up 19% year-over-year, driven by a 33% surge in transaction volume. The company achieved its first GAAP net income o...
- Marqeta reported Q1 2026 net revenue of $166 million, up 19% year-over-year, with gross profit reaching $118 million, also up 19%. Transaction volume grew 33% to $112 billion, marking the second consecutive quarter with TPV exceeding $100 billion. The company achieved its first GAAP net income of $8 million, with adjusted EBITDA surging 66% to $33 million and a 20% margin. Block's revenue concentration fell to 42%, as non-Block business grew at twice the pace, indicating successful customer diversification. Twelve of Marqeta's top 15 customers now operate in multiple countries, highlighting strong demand for multinational card issuing capabilities. BNPL growth remained robust at nearly 60% year-over-year, while expense management grew over 40%, driven by existing customer expansion. Management reiterated full-year net revenue guidance of 12-14% growth but lifted full-year adjusted EBITDA growth to the mid-to-high twenties%. Marqeta expects to be at GAAP breakeven in Q2 2026, with full-year net income guidance increased by $5 million to approximately $15 million. Block's new issuance decline is being pushed into the second half of the year, reducing the full-year gross profit headwind to 1.5 percentage points. The company is exploring stablecoin-backed card programs and agentic payment use cases, positioning its flexible credential technology for emerging fintech trends.
- company_name
- quarter
- +7 more takeaways
Arcus Biosciences Q1 2026 Earnings Call - Casdatifan Takes Center Stage in Kidney Cancer Push
Arcus Biosciences is pivoting hard into a new era of fully owned, late-stage development with casdatifan as the undisputed centerpiece. The company is accelerating enrollment in its phase III PEAK-1 k...
- 1. Full ownership of casdatifan marks a strategic inflection point for Arcus, eliminating partnership dependencies and allowing full control over development and commercialization.
- 2. Phase III PEAK-1 enrollment is accelerating and on track to complete by year-end 2026, targeting the IO-experienced second-line setting with a clear path to establish casdatifan plus cabozantinib as the new standard of care.
- 3. Management emphasizes casdatifan’s superior pharmacodynamic profile over belzutifan, citing sustained HIF-2 inhibition that translates to longer progression-free survival and higher response rates.
- +9 more takeaways
DHI Group Q1 2026 Earnings Call - ClearanceJobs Growth Offsets Tech Hiring Slowdown
DHI Group reported a mixed but strategically focused first quarter for 2026. ClearanceJobs drove the headline performance with 5% revenue growth and 7% bookings growth, buoyed by a $1 trillion U.S. de...
- ClearanceJobs revenue grew 5% year-over-year to $14.0 million, while bookings increased 7% to $18.0 million, highlighting the platform's role as the company's primary growth engine.
- The acquisition of Point Solutions Group (PSG) contributed $700,000 in revenue and bookings in its first partial quarter, with management projecting a full-year revenue uplift of approximately $6 million.
- Defense budget tailwinds are accelerating; the $1 trillion U.S. defense budget and NATO's 5% GDP spending targets are driving improved customer sentiment and demand for cleared tech talent.
- +7 more takeaways
Solventum Technologies Q1 2026 Earnings Call - Momentum and Margin Expansion Outpace Separation Headwinds
Solventum kicked off fiscal 2026 with a quarter that defied the noise. The company delivered organic sales growth and EPS that beat both plan and consensus, proving that the commercial engine is firin...
- Organic sales grew 2.1% in Q1 2026, beating expectations and setting a strong tone for the full year.
- EPS came in at $1.48, representing 11% growth and landing ahead of consensus.
- Gross margins expanded by 80 basis points year-over-year to 56.4%, driven by favorable mix, sales leverage, and programmatic savings.
- +7 more takeaways
Rapid7 Q1 2026 Earnings Call - AI-Driven Security Shift Fuels Core Platform Growth
Rapid7 delivered outperformance across all guided metrics in Q1 2026, with ARR of $832 million and non-GAAP operating income of $24 million, driven by sustained growth in its core Detection and Respon...
- Rapid7 exceeded Q1 2026 guidance, reporting $832 million in ARR and $24 million in non-GAAP operating income, with strong free cash flow of $33 million.
- Core platform solutions (D&R and Exposure Management) now represent over 80% of ARR, with D&R growth accelerating to 7% year-over-year, driven by MDR strength.
- The acquisition of Kenzo Security introduces an agentic AI platform that automates security operations, shifting focus from manual alert investigation to machine-speed remediation at scale.
- +7 more takeaways